Investigation of Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single Oral 10 mg BAY1101042 MR Tablet Dose in Male and Female Subjects With Renal Impairment and in Age-, Gender-, and Weight- Matched Healthy Subjects in a Single Center, Non-controlled, Open-label, Observational Design
Phase of Trial: Phase I
Latest Information Update: 28 Sep 2017
At a glance
- Drugs BAY 1101042 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Bayer
- 28 Aug 2017 Planned End Date changed from 31 May 2018 to 22 Aug 2018.
- 28 Aug 2017 Status changed from not yet recruiting to recruiting.
- 08 Aug 2017 New trial record